IFNG and neoplasm: Protein tyrosine phosphatase non-receptor type 2 (PTPN2) is considered to be a new target for tumor immunotherapy, and deletion of PTPN2 in tumor cells can strengthen immune response by enhancing interferon-γ (IFN-γ)-mediated effects on antigen presentation [30–33].